Nasal spray compositions exhibiting increased retention in the nasal
cavity
    4.
    发明授权
    Nasal spray compositions exhibiting increased retention in the nasal cavity 失效
    鼻喷雾组合物在鼻腔中表现出增加的保留性

    公开(公告)号:US5897858A

    公开(公告)日:1999-04-27

    申请号:US964038

    申请日:1997-11-04

    摘要: Aqueous nasal spray compositions containing:0.001-2% by weight/volume of a medicament selected from the group consisting of chlorpheniramine maleate, oxymetazoline hydrochloride and mixtures thereof;0.50 to 15.00% by weight/volume of a water soluble polymer selected from the group consisting of polyvinylpyrrolidone having an average molecular weight of about 10,000 to 360,000 and mixtures thereof;2.5 to 10.00% by weight/volume of polyethylene glycol;1.00 to 10.00% by weight/volume of a moisturizing agent other than polyethylene glycol;0.01 to 0.05% by weight/volume of disodium edetate;0.001 to 0.3% by weight/volume of an antimicrobial preservative;0.20 to 5.00% by weight/volume of an aromatic alcohol;a sufficient amount of a pharmaceutically acceptable buffer to maintain the pH of the composition within the range of about 4.0 to 8.0; andQS water.

    摘要翻译: 水性鼻喷雾剂组合物,其含有:0.001-2%(重量)/体积的选自马来酸氯苯那敏,盐酸羟甲唑啉及其混合物的药物; 0.50至15.00重量%/体积的选自平均分子量为约10,000至360,000的聚乙烯吡咯烷酮及其混合物的水溶性聚合物; 2.5至10.00重量%/体积的聚乙二醇; 1.00至10.00重量%/体积的除聚乙二醇之外的保湿剂; 0.01至0.05重量%/体积的乙二胺四乙酸二钠; 0.001〜0.3重量%/抗菌防腐剂体积; 0.20〜5.00重量%/芳族醇的体积; 足够量的药学上可接受的缓冲剂以将组合物的pH保持在约4.0-8.0的范围内; 和QS水。

    Nasal spray compositions
    6.
    发明授权
    Nasal spray compositions 失效
    鼻喷雾剂

    公开(公告)号:US5854269A

    公开(公告)日:1998-12-29

    申请号:US640767

    申请日:1996-08-06

    CPC分类号: A61K9/0043 A61K31/415

    摘要: An aqueous nasal decongestant composition containing oxymatazoline is disclosed which does not contain mercurial preservatives.

    摘要翻译: PCT No.PCT / US94 / 12945 Sec。 371日期:1996年8月5日 102(e)日期1996年8月5日PCT 1994年11月17日PCT公布。 公开号WO95 / 13810 日期:1995年5月26日公开了含有羟甲唑啉的含水鼻用减充血剂组合物,其中不含有汞防腐剂。